Trial · NCT02130557
Results by group71
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 71
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Major Molecular Response (MMR) at Month 12 | Bosutinib | 47.2 | 95% Confidence Interval 40.9 to 53.4 | percentage of participants | |
| Percentage of Participants With Major Molecular Response (MMR) at Month 12 | Imatinib | 36.9 | 95% Confidence Interval 30.8 to 43.0 | percentage of participants | |
| Percentage of Participants With Major Molecular Response (MMR) Up to Month 18 | Bosutinib | 61.0 | 95% Confidence Interval 54.9 to 67.1 | percentage of participants | |
| Percentage of Participants With Major Molecular Response (MMR) Up to Month 18 | Imatinib | 52.7 | 95% Confidence Interval 46.4 to 59.0 | percentage of participants | |
| Kaplan-Meier Estimate of Probability of Retaining Major Molecular Response (MMR) at Month 48 | Bosutinib | 92.2 | 95% Confidence Interval 86.8 to 95.4 | percentage of participants | |
| Kaplan-Meier Estimate of Probability of Retaining Major Molecular Response (MMR) at Month 48 | Imatinib | 92.0 | 95% Confidence Interval 85.9 to 95.5 | percentage of participants | |
| Percentage of Participants With Complete Cytogenetic Response (CCyR) Up to Month 12 | Bosutinib | 77.2 | 95% Confidence Interval 72.0 to 82.5 | percentage of participants | |
| Percentage of Participants With Complete Cytogenetic Response (CCyR) Up to Month 12 | Imatinib | 66.4 | 95% Confidence Interval 60.4 to 72.4 | percentage of participants | |
| Kaplan-Meier Estimate of Probability of Retaining Complete Cytogenetic Response (CCyR) at Month 48 | Bosutinib | 97.4 | 95% Confidence Interval 93.9 to 98.9 | percentage of participants | |
| Kaplan-Meier Estimate of Probability of Retaining Complete Cytogenetic Response (CCyR) at Month 48 | Imatinib | 93.7 | 95% Confidence Interval 88.9 to 96.5 | percentage of participants | |
| Cumulative Incidence of Event Free Survival (EFS) Events | Bosutinib | 6.9 | 95% Confidence Interval 4.2 to 10.5 | percentage of participants | |
| Cumulative Incidence of Event Free Survival (EFS) Events | Imatinib | 10.4 | 95% Confidence Interval 6.9 to 14.6 | percentage of participants | |
| Overall Survival (OS) Rate | Bosutinib | 94.9 | 95% Confidence Interval 91.1 to 97.0 | percentage of participants | |
| Overall Survival (OS) Rate | Imatinib | 94.0 | 95% Confidence Interval 90.1 to 96.4 | percentage of participants | |
| Summary of Trough Plasma Concentration by Complete Cytogenetic Response (CCyR) of Bosutinib | Bosutinib | Day 28 | 71.282 | Standard Deviation 46.0545 | nanogram per milliliter (ng/mL) |
| Summary of Trough Plasma Concentration by Complete Cytogenetic Response (CCyR) of Bosutinib | Bosutinib | Day 56 | 73.069 | Standard Deviation 45.1349 | nanogram per milliliter (ng/mL) |
| Summary of Trough Plasma Concentration by Complete Cytogenetic Response (CCyR) of Bosutinib | Bosutinib | Day 84 | 83.973 | Standard Deviation 64.3206 | nanogram per milliliter (ng/mL) |
| Summary of Trough Plasma Concentration by Major Molecular Response (MMR) of Bosutinib | Bosutinib | Day 28 | 75.050 | Standard Deviation 51.9551 | ng/mL |
| Summary of Trough Plasma Concentration by Major Molecular Response (MMR) of Bosutinib | Bosutinib | Day 56 | 78.437 | Standard Deviation 43.6019 | ng/mL |
| Summary of Trough Plasma Concentration by Major Molecular Response (MMR) of Bosutinib | Bosutinib | Day 84 | 91.081 | Standard Deviation 72.1500 | ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02130557/results